Browse the corpus

REFERENCES Bamat MK, Tremmel R, O’Neil JD, et al, “Uridine Triacetate: An Orally Administered Life-Saving Antidote for 5-FU Overdose,” J Clin Oncol , 28(15s):9084 [abstract 9084 from 2010 ASCO Annual Meeting]. Cartwright TH, Cohn A, Varkey JA, et al, “Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic Cancer,” J Clin Oncol , 2002, 20(1):160-4. [PubMed 11773165 ] Cassidy J, Tabernero J, Twelves C, et al, "XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer," J Clin Oncol , 2004, 22(11):2084-91. [PubMed 15169795 ] Haller DG, Cassidy J, Clarke S, et al, “Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines,” J Clin Oncol , 2008, 26(13):2118-23. [PubMed 18445840 ] Hennig IM, Naik JD, Brrown S, et al, “Severe Sequence-Specific Toxicity When Capecitabine Is Given After Fluorouracil and Leucovorin,” J Clin Oncol , 2008, 26(20):3411-7. [PubMed 18612156 ] Hoff PM, Ansari R, Batist G, et al, “Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study,” J Clin Oncol , 2001, 19(8):2282-92. [PubMed 11304782 ] Ishitsuka H, “Capecitabine: Preclinical Pharmacology Studies,” Invest New Drugs , 2000, 18(4):343-54. [PubMed 11081570 ] Johnston PG and Kaye S, “Capecitabine: A Novel Agent for the Treatment of Solid Tumors,” Anticancer Drugs , 2001, 12(8):639-46. [PubMed 11604550 ] Judson IR, Beale PJ, Trigo JM, et al, “A Human Capecitabine Excretion Balance and Pharmacokinetic Study After Administration of a Single Oral Dose of 14 C-Labelled Drug,” Invest New Drugs , 1999, 17(1):49-56. [PubMed 15173095 ] McGavin JK and Goa KL, “Capecitabine: A Review of Its Use in the Treatment of Advanced or Metastatic Colorectal Cancer,” Drugs , 2001, 61(15):2309-26. [PubMed 11772141 ] Morgan C, Tillett T, Braybrooke J, et al, “Management of Uncommon Chemotherapy-Induced Emergencies,” Lancet Oncol , 2011, 12(8):806-14. [PubMed 21276754 ] National Comprehensive Cancer Network® (NCCN), “Clinical Practice Guidelines in Oncology™: Prevention and Treatment of Colon Cancer,” Version 2.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/colon.pdf

Morgan C, Tillett T, Braybrooke J, et al, “Management of Uncommon Chemotherapy-Induced Emergencies,” Lancet Oncol , 2011, 12(8):806-14. [PubMed 21276754 ] National Comprehensive Cancer Network® (NCCN), “Clinical Practice Guidelines in Oncology™: Prevention and Treatment of Colon Cancer,” Version 2.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/colon.pdf National Comprehensive Cancer Network® (NCCN), “Clinical Practice Guidelines in Oncology™: Prevention and Treatment of Pancreatic Adenocarcinoma,” Version 1.2009. Available at file://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Schilsky RL, “Pharmacology and Clinical Status of Capecitabine,” Oncology , 2000, 14(9):1297-306. [PubMed 11033828 ] Twelves C, Wong A, Nowacki MP, et al, “Capecitabine as Adjuvant Treatment for Stage III Colon Cancer,” N Engl J Med , 2005, 352(26):2696-704. [PubMed 15987918 ] Van Cutsem E, Twelves C, Cassidy J, et al, “Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study,” J Clin Oncol , 2001, 19(21):4097-106. [PubMed 11689577 ] Videnovic A, Semenov I Chua-Adajar R, et al, “Capecitabine-Induced Multifocal Leukoencephalopathy: A Report of Five Cases,” Neurology , 2005, 65(11):1792-4. [PubMed 16237130 ] von Borstel R, O’Neil J, and Bamat M, “Vistonuridine: An Orally Administered, Life-Saving Antidote for 5-Fluorouracil (5FU) Overdose,” J Clin Oncol , 2009, 27(15S):9616 [abstract from 2009 ASCO Annual Meeting]. Wong M, Choo SP, and Tan EH, “Travel Warning With Capecitabine,” Ann Oncol , 2009, 20(7):2081. [PubMed 19470576 ] Topic 8839 Version 47.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.4 - C21.36 Licensed to: Southeast Alabama Med Ctr | Support Tag: [0504-122.72.76.133-424AE69C25-S244013.14]